CD47 and neoplasm: By recruiting additional immune cells to tumours and synergizing the response of innate and adaptive immunity, CD47 blockade has displayed tremendous pharmacological advantages for preventing tumour recurrence and treating advanced‐stage malignancies and complications [15].